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Abstract
Objective: To investigate the effects of melatonin treatment in a rat model of white matter damage (WMD) in the
developing brain. Additionally, we aim to delineate the cellular mechanisms of melatonin effect on the oligodendroglial cell
lineage.
Methods: A unilateral ligation of the uterine artery in pregnant rat at the embryonic day 17 induces fetal hypoxia and
subsequent growth restriction (GR) in neonatal pups. GR and control pups received a daily intra-peritoneal injection of
melatonin from birth to post-natal day (P) 3.
Results: Melatonin administration was associated with a dramatic decrease in microglial activation and astroglial reaction
compared to untreated GR pups. At P14, melatonin prevented white matter myelination defects with an increased number
of mature oligodendrocytes (APC-immunoreactive) in treated GR pups. Conversely, melatonin was not found to be
associated with an increased density of total oligodendrocytes (Olig2-immunoreactive), suggesting that melatonin is able to
promote oligodendrocyte maturation but not proliferation. These effects appear to be melatonin-receptor dependent and
were reproduced in vitro.
Interpretation: These data suggest that melatonin has a strong protective effect on developing damaged white matter
through decreased microglial activation and oligodendroglial maturation leading to a normalization of the myelination
process. Consequently, melatonin should be a considered as an effective neuroprotective candidate not only in perinatal
brain damage but also in inflammatory and demyelinating diseases observed in adults.
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Introduction
Brain injury and subsequent neurodevelopmental disabilities
resulting from premature birth are a major public health concern.
Indeed, preterm birth survivors can suffer from long term clinical,
educational and social problems: 10–15% of infants surviving from
very preterm delivery develop cerebral palsy and 50% show adverse
neurodevelopmental outcome at 30 months of age. Due to dramatic
improvement in perinatal management of high risk preterm
neonates, pathological conditions associated with neurological
impairment have changed over the past 10 years. Major focal
destructive lesions remain serious but have become less common. In
contrast, the most prominent neuropathological lesion is diffuse white
matterdamage(WMD) showinganassociation ofglialinjury together
with microglial activation and, ultimately, myelination defects.
Many factors are associated with WMD, including: infection,
hypoxia, ischemia, endocrine imbalances, genetic factors and
growth restriction [1–3]. In particular, intra uterine growth
retardation (IUGR) has been shown to be associated with both
white matter lesions and subsequent neurological impairment [4–
6] Based on these potential targets, a number of treatments for
neonatal brain injury including melatonin have been investigated
[7].
The pleiotropic effects of melatonin, combined with its anti-
oxidant, NMDA-blocking and anti-inflammatory properties,
probably make this molecule an ideal candidate for pre-clinical
studies. Moreover, this pharmacological agent has been proven
to be safe for neonates when crossing the blood-brain barrier.
Several experimental data have shown potent neuroprotective
effects of melatonin both in in vivo and in vitro.I np a r t i c u l a r ,
melatonin acts as a direct and indirect antioxidant, specifically as
a powerful scavenger of superoxide anion and stimulator of the
synthesis of anti-oxidant enzymes. However, the consequences
of melatonin treatment on the myelination process remain
PLoS ONE | www.plosone.org 1 September 2009 | Volume 4 | Issue 9 | e7128largely underexplored. Nonetheless, this question is crucial to
thoroughly assess the potential impact of melatonin on
myelination repair in perinatal and adult demyelinating
diseases.
We addressed this question by testing melatonin treatment in a
recently described rat model closely mimicking WMD observed in
very preterm neonates [8]. Our data show that melatonin has a
powerful protective effect on developing white matter subjected to
an antenatal hypoxic-ischemic insult. Melatonin acts through its
specific receptors by promoting oligodendroglial maturation and
myelination repair together with modulation of astrogliosis and
microglial activation in vivo and in vitro. Our results suggest that
melatonin could be an effective neuroprotective candidate not only
in perinatal white matter damage but also in inflammatory and
demyelinating white matter diseases observed in adult.
Materials and Methods
Uterine artery ligation
Unilateral ligation of the intra-uterine artery was performed on
pregnant Sprague-Dawley rat (Janvier, Le Genest-St-Isle, France)
during embryonic day 17 (E17) [8]. The mean weight of control
pups at birth in our animal facilities was 6.2460.37 g (n=56). In
each litter, the pups were separated into two groups according to
birth weight: control pups and severely growth restricted (GR)
pups weighting less than 5.50 g (6.34 g–2 S.D.). Only the most
severely GR pups were considered as born from the ligated horn
to avoid any bias between the two groups. All experiments were
carried out in compliance with ethical standards of our institution
(French National Institute for Health and Medical Research,
INSERM) and with the recommendations of the National
Research Council’s Guide for the Care and Use of Laboratory
Animals.
Experimental groups
Pups from at least three different litters were used in each
experimental group. From birth (P0) to postnatal day 3 (P3),
controls and GR pups received a daily i.p. injection with one of the
following drugs (or combination of drugs) diluted in a final volume
of 5 ml: 0.002 mg/kg/d to 20 mg/kg/d melatonin (Sigma),
5.0 mg/kg luzindole (Sigma) +/2 20 mg/kg/d melatonin.
Luzindole blocks melatonin receptors MT1 and MT2 with
comparable affinities (affinity selectivity ratio MT1/MT2=15.5).
To ensure that there were no differences in circadian rhythm
between experimental groups, all rat pups were injected once a
day at noon.
Immunocytochemistry
In each experimental group, we studied 6 to 10 pups on P3 and
P14 in three separate experiments. Animals were sacrificed under
anaesthesia with inhaled isoflurance (Abbott France, Rungis,
France). Brain tissues were immersed in formol 4% during 5 days,
embedded in paraffin and cut into 10-mm-thick sections.
Immunolabeling with the primary antibody listed in Table 1
was visualized using the streptavidin-biotin-peroxydase method, as
previously described [8]. Olig2 marker was used to visualize all
oligodendrocytes, APC and MBP to detect post-mitotic oligoden-
drocytes and myelinated fibers, respectively. Most of Olig2 nuclei
did not colocalized with GFAP+ cells (Figure S1). Tomato-lectin-,
Olig2- and Ki67-immunoreactive cells were revealed using
streptatividin, anti-rabbit IgG antibody and anti-mouse IgG
antibody coupled to the red fluorescent marker cyanine 3 (Jackson
Immunoresearch laboratories, West Grove, PA). Double labelings
were performed with secondary antibodies coupled to the green
fluorescent marker Fluoroprobe S488 (Interchim, Montluc ¸on,
France) or red fluorescent marker cyanine 3 (Jackson Immunor-
esearch laboratories, West Grove, PA) fluorescent markers.
Quantitative measurements
All quantitative measurements were done by observers who
were blinded to the experimental group of the studied animal.
Immunoreactive cells. Immunoreactive cells were counted
in the white matter underlying the cingular cortex (+2.16 to
20.36 mm from the bregma) on at least 4 non continuous sections
(alternatively, in right or left hemisphere) at P3 and P14.
Immunoreactive cells were counted within a 0.065 mm
2 grid (at
6400 magnification), in at least 6 animals per group.
Optical density of MBP-positive fibers. The optical density
of MBP-immunoreactive fibers was measured in the thickest white
matter inrodents,iecingular white matter assessed incoronalsections
(+2.16 to 20.36 mm from the bregma). At least 4 sections of 6 to 10
animals per group were examined on P14. Optical density was
measured at 6100 magnification using a computerized image
analysis system (ImageJ, NIH, MA, http://rsb.info.nih.gov/ij/) that
read optical density as grey levels. Nonspecific background densities
were measured at each brain level in a region devoid of MBP
immunostaining and were substracted from the cingulum values.
TUNEL staining
In P3 animals, dying cells in the white matter were detected using
TUNEL as previously described [3] and counted in 4 sections each
from a single hemisphere of at least 6 animals per treatment group.
Table 1. Primary antibodies used for immunohistochemistry analyses.
Markers Labeled structures Manufacturer Dilution
Tomato-lectin Resident, activated microglia and blood vessels. Vector, Burlingame, CA, USA 1/500
GFAP Astrocytes Sigma Biosciences, St Louis, MO, USA 1/1000
Ki67 Proliferating cells BD Biosciences France, Le-Pont-De-Claix, France. 1/100
Olig2 oligodendroglial lineage IBL, Hamburg, Germany 1/200
APC post-mitotic oligodendrocytes Calbiochem, La Jolla, CA, USA 1/500
MBP Myelinated fibers Sigma Biosciences, St Louis, MO
USA
1/1000
MT1 (Mel-1A) Melatonin receptor 1 Santa Cruz, Santa Cruz, CA, USA 1/100
MT2 (Mel-1B) Melatonin receptor 2 Santa Cruz, Santa Cruz, CA, USA 1/100
doi:10.1371/journal.pone.0007128.t001
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electron microscopy
The morphology of melatonin-treated cingulate white matter was
studied by electron microscopy. First, brain were sagitally cut in
100 mm-thick vibratome sections to allow for better penetration of the
reagent and postfixed for 10 min at room temperature with 1%
osmium tetroxide (Heraeus Chemicals,P o r tE l i s a b e t h ,S o u t hA f r i c a )i n
phosphate buffer. After a 10 min wash in a phosphate buffer, sections
were dehydrated in graded alcohol baths and successively incubated in
alcohol/araldite (v/v) for 1 h at 37uC, araldite (Fluka, Steinheim,
Switzerland) for 15 h at 37uC, and araldite supplemented with 2%
accelerator (Fluka) for 3 h at 37uC. Sections were then embedded in
araldite (2 days at 60 uC). Silver ultrathin sections of the cingulate white
matter (about 70 nm-thick) were made using an ultramicrotome (LKB,
Bromma, Sweden) and then collected on copper grids. They were
counterstained with lead citrate for 10 min at room temperature in a
drying chamber and examined using a Leo 912 (Carl Zeiss, Le pecq,
France) electron microscope. In order to study the qualitative aspect of
the myelin, the number of axons surrounded with an uncompacted
myelin sheet was reported as the total number of myelinated axons
counted of 20 electromicrographes at magnification 64000. A
qualitative score was applied to each myelinated axon (see table 2).
Cell cultures and cell treatments
Primary neuronal cultures (.98% purity assessed by MAP-2
(microtubule-associated protein-2) immunostaining, data not
shown) were prepared using E18 embryonic rats. For oligodendro-
cyte, astrocyteand microglia primary cultures,cell populations were
isolated from P0–P2 newborn rats and subsequently cultured
according to published protocols from 6 days to 3 weeks [9–11].
Purityofoligodendroglialcellcultureswasassessed usingO4,GFAP
and tomato-lectin staining: at DIV10, 65–70% of the cells were
found O4+, 25–30% GFAP+ and less than 5% Tomato-lectin+ in
three separate experiments.
DNA-free total mRNA from cell cultures and cortical plate from
rat aged from 1, 7 and 14 day-old rats were extracted from these
cells using the previously published protocol [12].
Oligodendoglial cells were exposed to melatonin at 1 and
100 mmol diluted in DMSO 20% after 6, 8 and 10 days of culture.
As our in vivo model is characterized by early microglial activation
within developing white matter we further tested the ability of
melatonin to modulate microglial activation in vitro. We used a
well-established model of microglia subjected to LPS leading to
both morphological and immunocytochemical changes and a
dramatic increase in cytokines and free radicals production. In
microglial cell cultures, the melatonin treatment was performed
after 5 days of culture, 12 h before and at the same time as LPS
exposure (100 ng/ml LPS) (Sigma, St Louis, MO).
Immunocytochemistry and immunofluorescence
microscopy on cell cultures
After treatments, cells were fixed with 4% paraformaldehyde in
PBS for 10 min at room temperature, washed 3 times with PBS, and
blocked with PBST (PBS 1x, pH 7.4, 0.1% Triton X-100) containing
5% goat serum for 1 hr at room temperature. The coverslips were
incubated with mouse monoclonal antibodies O4 (1:100 dilution, gift
fromDr.StevenE.Pfeiffer,UniversityofConnecticutHealth Center,
Farmington, CT), tomato lectin (1:1000, Vector, Burlingame) and
MBP (1:1000, Chemicon, Temicula, CA) overnight at 4uC. The
appropriate secondary antibody was conjugated with either Alexia
488 or Alexia 594 (Molecular Probes Inc., Eugene, OR), added to the
coverslips and incubated for 1 hr. Nuclei were stained by adding
Hoechst 33258 at a final concentration of 2 mg/ml for 1 min. The
coverslips were mounted onto glass slides with FluoroMount and kept
dark at 4uC. Cell images were captured with a fluorescence
microscope equipped with a digital camera (Leica DMRB with
Apogee Instruments Inc.). Quantification of labelled cells were based
either on the density of immunoreactive cells compared to the total
number of nuclei (O4 and MBP, 6400 magnification) or the optical
density of tomato-lectin immunoreactivity using ImageJ analysis
system at 6200 magnification.
Quantitative real-time PCR
The DNA-free total RNA from control and GR brain cortex
including white matter was obtained using a protocol adapted from
Chomczynski and Sacchi
12. The following oligonucleotides 59-
ATTGTCAAGTTAGTGCCTTCC-39 and 59-TTGAGACTGT-
GGCAAATGTAG-39,5 9-GTCATTGGCTCTGTCTTCAAC-39
and 59-GTAGGTCGCACTGTGACAGAT-39 were used as sense
and antisense primers, for MT1 and MT2. The nature of the
amplified DNA was confirmed by sequencing. To standardize gene
expression across samples, we first compared the expression levels of
four well-known housekeeping genes (glyceraldehyde-3-phosphate
dehydrogenase [GAPDH], b2-microglobulin, hypoxanthine-guanine
phosphoribosyltransferase [HPRT], and b-glucoronidase) within the
samples. For reverse transcription, we used 600 ng of total RNA and
the Iscript cDNA synthesis kit (Bio-Rad, Hercules, CA). Real-time
PCR was set up using sybergreen-containing supermix (Bio-Rad) for
50 cycles with a three-step program (25 sec denaturation at 96uC,
3 0 s e ca n n e a l i n ga t6 0 uC, and 30 sec extension at 72uC).
Amplification specificity was assessed by melting curve analyses.
Each experiment was run twice with a least 6 animals per group, and
in both cases, samples were assessed in triplicate.
Statistical analysis
All data were reported as means 6 S.E.M. Analysis of variance
was performed with age and groups (PBS- and melatonin-treated
controls and GR pups) as the factors, and the Newman-Keuls
post-test was used. Statistical tests were run on GraphPad Prism
version 4.00 (GraphPad Software, San Diego, CA).
Results
Melatonin attenuates myelination defect in growth
restricted pups
Systemictreatment using 20 mg/kg/dmelatoningivenwithin the
first 3 postnatal days was associated with a significant 58%
attenuation of myelination defects detected in the cingulate white
matter in P14 GR pups (p,0.001) (Figures 1A–E). Similar results
were observed in the genu of the corpus callosum (Figure 2A–E).
This effect was observed in most of GR pups, however, the most
severely growth restricted (below 4.5 g, corresponding to birth
Table 2. Quantitative analysis of the optical density of myelin
sheets in the cingulate white matter of controls and GR pups
with or without melatonin 20 mg/kg.
Group Myelin sheet O.D.
Controls 95.260.4
GR pups 58.760.7*
GR pups+melatonin 82.560.8
Data are expressed mean 6 S.E.M. Asterisk represent significant difference with
controls (* p,0.05 with one way ANOVA and Newman-Keuls multiple
comparision test).
doi:10.1371/journal.pone.0007128.t002
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PLoS ONE | www.plosone.org 3 September 2009 | Volume 4 | Issue 9 | e7128Figure 1. Melatonin attenuates myelination defect in the cingulum. (A–D) Cingulate white matter MBP-immunoreactivity in P14 rat pups
demonstrating that myelin content was defective in PBS-treated GR pups (B) compared to PBS- (A) and melatonin-treated controls (C). In contrast,
melatonin-treated animals (D) showed an MBP-immunoreactivity density similar to controls. Bars=200 mm. (E) Quantitative analysis of the MBP-positive
fibers optical density in the cingulate white matter of controls and GR pups treated with PBS or with melatonin 20 mg/kg. The area of optic density
measurement is indicated by an asterisk in (A–D). Statistical analysis compared either control and GR pups or untreated and treated GR pups. (**p,0.01
and ***p,0.001 using one-way ANOVA with the Newman-Keuls correction). (F) Scattered plot representation of MBP-positive fibers immunoreactivity
densityinthecingulatewhitematterofPBS-andmelatonin-treatedcontrolsandGRpupsatP14accordingtotheirbirthweight.Squares(inred) andline
represent PBS-treated animals, triangles (in blue) and line represent melatonin-treated animals. Dotted-lines represents weight of 5.50 g and 5.87g ,
respectively the upper limit (22 SD) of GR animals birth weight and the lower limit (21 SD) of control animals birth weight.
doi:10.1371/journal.pone.0007128.g001
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treatment (Figure 1F). For birth weights greater than 4.5 g, the
melatonin treatment was associated with a remarkably stabilized
MBP density regardless the birth weight, in contrast to untreated
animals in which myelin content appeared closely correlated with
birth weight (Figure 1F). Administration of melatonin induced a
dose-dependant effect on the density of MBP-positive fibers in the
cingulate white matter in GR pups (Figure 3A). A statistically
significant effect of melatonin was observed with a minimal
administration of 0.2 mg/kg/d melatonin. No effect of melatonin
on both body temperature and weight gain during the first 7 days
has been reported (data not shown). Similarly, brain weight gainwas
not found different during the first 14 days with or without
melatonin treatment (table S1). No statistically significant difference
in oligodendroglial cell death (TUNEL staining) was observed
between treated and control rat pups at P3 (Figure S2). Finally,
melatonin treatment during the first days of life (P0–P3) was not
associated with any alteration in myelin content in the normal
developing brain (both incingulumand corpuscallosum,Figure S3).
In melatonin-exposed GR rats, the blockage of melatonin
receptors, using luzindole co-treatment, eliminated the neuropro-
tective effect of melatonin on white matter myelination (Figure 3B).
Figure 2. Melatonin attenuates myelination defect in the corpus callosum. (A–D) White matter MBP-immunoreactivity in P14 rat pups
demonstrating that myelin content was defective in the genu of the corpus callosum in PBS-treated GR pups (B) compared to PBS- (A) and melatonin-
treated controls (C). In contrast, melatonin-treated animals (D) showed an MBP-immunoreactivity density similar to controls. Bars=200 mm. (E)
Quantitative analysis of the MBP-positive fibers optical density in the corpus callosum white matter of controls and GR pups treated with PBS or with
melatonin 20 mg/kg. The area of optic density measurement is indicated by a square in (A–D). Statistical analysis compared either control and GR
pups or untreated and treated GR pups. (***p,0.001 using one-way ANOVA with the Newman-Keuls correction).
doi:10.1371/journal.pone.0007128.g002
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treatment did not modify MBP-immunoreactivity cingulate white
matter. Luzindole alone did not potentiate the myelin defect
observed in GR pups (data not shown).
Melatonin improves the ultrastructural myelin aspect in
GR pups
Further experiments using electronic microscopy demonstrated
ultrastructural quantitative and qualitative effects of melatonin on
myelinated axons of rat pups that are subjected to antenatal
uterine ligation. In PBS- or melatonin-treated control P14 pups,
the developing white matter exhibited a high density of cells and
myelinated ovoid axons with well-compacted myelin sheets
(Figures 4A, 4D). In contrast, PBS-treated GR pups showed
dramatic cingulate white matter damage including a disorganized
structure of the developing white matter with undermyelinated
and swollen axons (Figure 4B). In most of cases, myelinated axons
were surrounded with uncompacted myelin sheets (table 2).
Melatonin treatment of GR pups was associated with a
quantitative and qualitative improvement of the myelin ultra-
structural aspect. Indeed, myelin features in treated animals were
characterized by a good compaction of the myelin sheet around
axons (table 3; Figures 4C, 4F). Thirty two percent of myelinated
axons observed in untreated GR animals were found embedded
with compacted myelin sheets compared to 79% in controls and
69% in treated GR animals. Conversely, melatonin treatment was
unable to restore cellular and axonal density suggesting a specific
effect on myelination process (Figures 4E, 4F). Similarly,
melatonin treatment was not able to change the immunocyto-
chemical aspect of RT-97-positive axons in both control and GR
pups (data not shown).
Melatonin treatment promotes oligodendroglial
maturation in GR pups
To further delineate the cellular target of melatonin treatment,
we asked the question whether melatonin could impact the
oligodendroglial lineage. To answer this question, the effect of
melatonin treatment on oligodendrocyte density was assessed
using various immunocytochemical markers (see methods). The
cingulate white matter of GR pups appeared to be depleted in
total (Olig2+) and mature (APC+) oligodendrocytes at P14
(Figures 5A, 5B) as well as P3 (data not shown). Melatonin
treatment was not able to restore the Olig2 positive-oligodendro-
cyte density in the cingulate white matter as well as the adjacent
corpus callosum in GR pups (Figure 5A). In contrast, melatonin-
treatment significantly (p,0.05) reduced the decrease of APC+
oligodendrocytes density observed in cingulate white matter of GR
rat pups at P14 (Figures 5B–F). Moreover, using Olig2/APC
double-labelling immunocytochemistry, 63% of Olig2+ oligoden-
drocytes were found APC+ in untreated GR pups compared to
more than 92% in melatonin treated P14 GR pups (p,0.05).
Conversely, melatonin was not found to be associated with any
change in cell proliferation in the developing white matter as
assessed using Ki67 immunolabeling at P3 and P14 (Figure S4).
Altogether, these data strongly suggest that melatonin treatment
promotes oligodendroglial maturation in GR rat pups.
Melatonin treatment is associated with a decrease of glial
activation in GR pups
Growth restriction induced by antenatal hypoxia was associated
with a protracted increase of microglial activation in the cingulate
white matter [7]. Thus, we investigated the consequences of
melatonin treatment on microglial activation in antenatal hypoxia-
exposed neonatal rats. In cingulum white matter, melatonin-treated
GR pups exhibited a significantly decreased density of activated
microglial cells compared to PBS-treated GR rat at P3 and P14
(Figure 6A). During the same developmental stages, melatonin
treatment did not modify microglial activity in the cingulate white
matterof controls. An increased densityof GFAP-positive astrocytes
in the cingulate white matter was observed in P14 GR rats
compared to controls. Furthermore, reactive astrocytes from GR
pups had a protoplasmic profile, with a bigger cell body and more
Figure 3. Melatonin effect is dose-dependent and mediated by
its specific receptors. (A) Cingulate white matter MBP-immunoreac-
tivity optical density in P14 GR pups compared to controls demon-
strating that melatonin was able to restore normal MBP content with a
minimal dose of 0.2 mg/kg. Controls and treated GR animals were
compared to untreated GR pups. *p,0.05 and ***p,0.001 using one-
way ANOVA with the Newman-Keuls correction. (B) The melatonin
effect on myelination was reversed when melatonin was co-injected
with luzindole, a specific MT1/MT2 antagonist. **p,0.01, NS: not
significant using one-way ANOVA with the Newman-Keuls correction.
doi:10.1371/journal.pone.0007128.g003
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developmental stages, melatonin treatment was associated with a
significantly decrease in reactive astrocyte density in GR pups
compared to controls (p,0.01) (Figure 6B). Melatonin-treated
controls did not exhibit any modification of cingulate white matter
astroglial profile and density.
Figure 4. Melatonin improves the ultrastructural myelin aspect in GR pups. (A–F) Cingulate white matter ultrastructural aspect observed
using electron microscopy. PBS-treated GR pups (B, C) exhibited swollen axons (marked with an asterisk) and dramatically low cellular, axonal and
myelinated axons density compared to PBS- (A) and melatonin-treated controls (D). Note the large proportion of myelinated axons surrounded with
uncompacted myelin sheets (arrows) in PBS-treated GR-pups (B, C). In contrast, melatonin-treated GR animals exhibited a high proportion of well-
compacted myelination processes, similar to controls (E–F). Interestingly, melatonin treatment appeared to not be able to restore a normal axonal
aspect within the developing white matter (E). Swollen axons were marked with an asterisk. Quantitative analysis of myelin ultrastructural aspect was
reported in table 2.
doi:10.1371/journal.pone.0007128.g004
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white matter glial cells
Because the effect of melatonin is recognized to be mediated
through specific G-protein coupled receptors MT1 and MT2
(antagonized by luzindole), we next asked the question whether
these two receptors were expressed in the various cell types
populating the developing white matter at the time melatonin
treatment was given. We tested this using RT-PCR in vitro in
neurons, microglia, astrocytes and immature oligodendrocytes, all
cell types populating the developing white matter. MT1 and MT2
appeared to be strongly expressed in both astrocytes and
microglial cells, and to a lesser extent in neurons and immature
oligodendrocytes (Figure 7A). Immunocytofluorescent stainings
using MT1 (Mel-1A) and MT2 (Mel-1B) antibodies revealed
similar expression pattern (Figure 7B).
Melatonin induces oligodendroglial maturation and
modulates microglial activation in vitro
Developing oligodendrocytes and microglia were the two major
cell types involved in the main features of white matter damage in
our rat model. Since we found melatonin receptors to be expressed
in both cell types, we further investigated the impact of melatonin
exposure in vitro. In the oligodendroglial lineage model we
observed that 1 mmol melatonin exposure was associated with an
enhancement of oligodendroglial maturation to myelinating
oligodendrocytes (Figures 8A, 8B). Indeed, MBP positive cell
density increased more than two-fold at DIV 10 after melatonin
treatment compared to DMSO or untreated cells (p,0.01). In
addition, APC and PLP immunostainings were also found
increased after melatonin treatment in oligodendrocyte cell
cultures (Figure S5). Similar results were obtained using 100 mmol
melatonin (data not shown).
Microglial activation was considered as a key feature in our in
vivo model, likely to be responsible for subsequent myelination
deficit. To mimic this feature in vitro, we used LPS to activate
microglial cells. Because melatonin treatment was associated with
a dramatic effect on microglial activation in vivo, we tested the
ability of melatonin to modulate the effect of LPS-induced
microglial activation in vitro. Microglial cells were pre-treated with
either 1 or 100 mmol melatonin 12 h hours before and then
together with LPS exposure. LPS-treated microglial cells exhibited
an amyboid shape and a significant increase in tomatolecin
immunoreactivity density compared to non-activated cells. In
contrast, melatonin exposure completely reversed the LPS effect
and prevented activation of microglial cells (Figures 8C, 8D). A
similar effect was observed using two different cellular densities of
microglial cells (data not shown).
Discussion
In this study we investigated the underlining cellular mecha-
nisms responsible for the neuroprotective effects of melatonin
treatment in antenatal hypoxia-induced white matter injury in the
developing rat brain. We have demonstrated that melatonin acts
in a neuroprotective fashion by promoting oligodendroglial
maturation together with decreased microglial activation, both in
vivo and in vitro. We recently reported a rat model inducing IUGR
and white matter damage after prenatal hypoxia and deprivation
of nutritional and maternal factors [13]. As previously described,
GR pups exhibited white matter damage characterized by
increased microglial activation, increased astrogliosis, leading to
a protracted oligodendrocytes depletion associated with myelina-
tion defects [7,14]. In this study, electron microscopy analysis of
the injured white matter refined the abnormal aspect of the
developing white matter. The few myelinated axons were mostly
embedded with a poorly compacted myelin. MBP proteins have
been recognized to have a crucial role in myelin compaction by
intercalating between phospholipidic sheets and interacting with
lipids and proteolipids [15,16]. Similarly, Shiverer mice, a natural
mutant for MBP gene, exhibit hypomyelination and produce
poorly compacted myelin around axons [17,18].
In GR animals, the white matter also appeared with large areas
of swollen axons, suggesting protracted oedematous damage.
Despite no detectable change in axonal neurofilament distribution,
ultrastructural analysis of neonatal white matter clearly demon-
strates that growth restriction observed in our model is associated
with oligopathy and myelinopathy.
Several experimental studies have highlighted that melatonin
has neuroprotective benefits when given as either a prophylactic or
curative treatment in several animal models of brain damage.
Most of such studies have analyzed the effect of melatonin in
traumatic or brain focal ischemia in adult rodent [19–21]. In such
models, melatonin was found to decrease the volume of brain
damage, neuronal cell death, oxidative stress, DNA damage,
mitochondrial insult and to improve neurobehavioural outcome.
Furthermore melatonin exerts its neuroprotective benefits against
excitotoxic insult both in vitro [22,23], ex vivo in hippocampal
neurons in adult rats [24] or in vivo [4]. Melatonin has also been
studied in a large animal model of preterm brain injury in fetal
sheep subjected to umbilical cord occlusion [25]. This study
demonstrated that melatonin attenuates cell death in the fetal
brain in association with a reduced inflammatory response in the
blood and the brain following intrauterine asphyxia in mid-
gestation fetal sheep.
In mature melatonin-deficient rats, lesions induced by
hypoxia-ischemia were observed to be larger than in controls
Table 3. Ultrastructural analysis of myelinated fibers in controls and GR pups with electron microscopy.
Group Qualitative myelin aspect score % of myelinated axons embedded with compacted myelin sheets
Controls 2.660.1 79.1(67.5)%
GR pups 1.160.5* 32.2(67.8)%*
GR pups+melatonin 2.660.1 68.6(612.2)%
Qualitative myelin aspect score:
0: no myelinated axons found;
1: very thin myelin sheet;
2: uncompacted myelin sheets;
3: normally compacted myelin sheets.
Data are expressed mean 6 S.E.M. Asterisk represent significant difference with controls (* p,0.05 with one way ANOVA and Newman-Keuls multiple comparision test).
doi:10.1371/journal.pone.0007128.t003
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However newborn animals and humans have low levels of
melatonin and the melatonin receptor antagonist luzindole does
not potentiate excitotoxic cerebral white matter lesions in
rodents, suggesting that endogenous melatonin is not sufficient
to protect the newborn. For exactly this reason, melatonin
treatment could be relevant in a clinical setting in preterm
human neonates.
Figure 5. Melatonin promotes oligodendroglial maturation. (A) Quantitative analysis of Olig2-immunoreactive cells in the cingulate white
matter at P14. Melatonin treatment was found to not be able to reverse the loss of total oligodendrocytes observed in GR pups. (B) Quantitative
analysis of APC-immunoreactive cells in the cingulate white matter at P14. Melatonin treatment was associated with a significant reduction in mature
oligodendrocytes deficit observed in GR pups. *p,0.05 and ***p,0.001 using one-way ANOVA with the Newman-Keuls correction. (C–F) PBS-treated
GR pups exhibited a defective mature (APC-immunoreative) oligodendrocyte density (D) compared to PBS- and melatonin-treated controls (C, E).
Melatonin treatment partially restored mature oligodendrocytes density (F). Microphotographes show cingulate white matter with the standardized
counting area indicated by dotted lines. V: ventricule. cc=corpus callosum underlying the cingulum. Bars=200 mm.
doi:10.1371/journal.pone.0007128.g005
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initial appearance of lesions in a mouse model of excitotoxic-
induced white matter damage, but is able to promote axonal
regrowth or sprouting [4]. However, the effect of melatonin on
myelination and subsequent white matter repair has not yet been
studied. Previous studies have shown that white matter damage
observed in our model was characterized by a depletion in post-
mitotic oligodendrocytes (APC+ cells) rather than pre-oligoden-
drocytes (O4+ cells) [14]. In the present study, the olig2
immunolabeling suggest that the entire oligodendroglial lineage
is defective in GR animals’ white matter. It is relevant to point out
that melatonin-induced preservation of myelination is associated
with partial recovering of mature APC+ oligodendrocytes (despite
a deficit in total oligodendroglial population). Consequently, we
speculate that the main target of melatonin treatment could be the
maturation process of the oligodendrocyte lineage. This hypothesis
is supported by several lines of evidence: melatonin treatment
increased oligodendrocyte maturation and MBP-immunoreactiv-
ity normalization in vivo. Melatonin treatment was associated with
a restoration of myelin sheet compaction surrounding axons in GR
pups white matter. This result is consistent with MBP-immuno-
reactivity normalization as MBP is crucial for myelin sheet
compaction [15,16]. Finally, melatonin was able to improve
Figure 6. Melatonin is associated with a decreased glial
activation. (A) Quantitative analysis of amyboid tomato-lectin-
immunoreactive cells in the cingulate white matter in P3 and P14 rat
pups. PBS-treated GR pups exhibited a significant increase in density of
reactive microglia compared to PBS- and melatonin-treated controls. In
contrast, microglial activation in melatonin-treated GR animals was
similar to controls. (B) Quantitative analysis of GFAP-immunoreactive
cells in the cingulate white matter in P14 rat pups. PBS-treated GR pups
exhibited a significant increase in reactive astrocyte density compared
to controls. Melatonin-treatment was associated with a normal
astroglial density in treated-GR pups compared to controls. Analysis
was performed using two-way ANOVA with the Newman-Keuls
correction *p,0.05, **p,0.01 and ***p,0.001 indicating significant
differences between GR and control rat pups. #p,0.05, ##p,0.01
and ###p,0.001 indicating significant differences between PBS- and
melatonin-treated GR animals.
doi:10.1371/journal.pone.0007128.g006
Figure 7. Melatonin receptors are differentially expressed in
white matter glial cells in vitro. (A) Relative expression of MT1
(amplicon: 109 bp) and MT2 (amplicon: 75 bp) mRNA in various cell
cultures including astrocytes, neurons, immature oligodendrocytes and
microglia.(B) Immuno-labelling of various primary cell cultures (microg-
lia, neuron, oligodendrocytes, astrocytes) using either MT1 or MT2
markers. Arrows show small fraction of astrocytes contaminating
oligodendrocyte cell cultures.
doi:10.1371/journal.pone.0007128.g007
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PLoS ONE | www.plosone.org 10 September 2009 | Volume 4 | Issue 9 | e7128Figure8. Melatonin promotes myelin production and prevents LPS-induced microglial activation in vitro. (A)Immuno-labelling of primary
oligodendroglial cell cultures using either O4 or MBP at DIV6 or DIV10 with or without treatment with 1 mmol melatonin. (B) Quantitative analysis of the
density of O4 or MBP immunoreactive cells at DIV6 and DIV10 with or without treatment with 1 mmol melatonin. **p,0.01, using one-way ANOVA with
the Newman-Keuls correction. (D) Immuno-labelling of microglial cell cultures using tomato-lectin in presence of LPS with and without 1 mmol
melatonin. Note the marked increase in tomato-lectin immunoreactivity in microglia subjected to LPS. (C)Quantitative analysis of the densityof tomato-
lectin positive cells in presence of LPS with and without 1 mmol melatonin. ***p,0.001, using two-way ANOVA with the Newman-Keuls correction.
doi:10.1371/journal.pone.0007128.g008
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tion in vitro or in vivo.
The mechanism(s) behind the neuroprotective benefits of
melatonin are not yet fully elucidated. To date, it has been shown
that the effect of melatonin include endocrine, autocrine and
paracrine actions, decreased inflammation, and antioxidant effects.
Melatonin has also some benefits in other ‘‘toxic models’’ of
perinatal brain damage based on excitotoxic cascade [4]. However,
in most of perinatal brain damage animal models reported, immune
cell activation frequently occurs [1] and melatonin effect appears to
be closely linked to inflammation modulation. Some of these actions
are receptor-mediated, while others are direct. We demonstrate
here that the two major subtypes of melatonin-receptors MT1 and
MT2 were expressed by microglia, astrocytes and oligodendrocytes,
i.e. all cell types populating the immature white matter. Assuming
that the cingulate myelination deficit was associated with focal
cingulate microglial activation in our model and that immature
oligodendrocytes are highly vulnerable in an inflammatory context
[27,28], it is reasonable to hypothesize that melatonin could restore
normal oligodendrocyte maturation by reducing white matter
inflammation. In fact, in the present study, we found melatonin
treatment to be associated with a reduction of microglial activation
in GR pups at P3 in vivo and LPS-induced microglial activation in
vitro. This result is in agreement with previous studies [29,30]. The
signalling pathways involved in the maturation effect of melatonin
on developing oligodendrocytes remain unclear. However, several
effects of melatonin through its receptors may account for its ability
to prevent oligodendroglial damage: free radical scavenger
production by activated microglia [17,31,32], improvement of
membrane fluidity and reduction of edema and polymorphonuclear
cell infiltration into damaged tissue, prevention of translocation of
the nuclear factor-kappa-B to the nucleus and the subsequent
reduction of pro-inflammatory cytokines expression, which play a
relevant role in the inflammatory reaction [33,34]. In addition,
melatonin could modulate astrocyte reactivity or death through an
upregulation of astrocytic anti-oxidative defenses [35,36].
In conclusion, our results demonstrate that melatonin could
preserve axonal myelination in adverse conditions. The neuro-
protective pathway appears to implicate both melatonin receptors
and inflammatory modulation, leading to a promotion of
oligodendrocyte maturation. The present study also delineates
the cellular mechanisms of melatonin neuroprotective benefits.
Furthermore, our data strongly suggest that melatonin could be of
great interest not only in perinatal white matter damage but also as
a potential neuroprotective strategy for myelinopathy diseases
observed in adults.
Supporting Information
Figure S1 Double immunolabeling using GFAP (astrocytes in
green, arrows) and Olig2 (oligodendrocytes in red, arrowheads)
markers in cingulate white matter. Most of Olig2 nuclei did not
colocalized with GFAP+ cells in the developing white matter.
Found at: doi:10.1371/journal.pone.0007128.s001 (7.60 MB TIF)
Figure S2 Quantification of TUNEL+ cells detected in the
hemispheric white matter at P3 from control (Ctl) and GR rat
pups treated or not with Melatonin (Mel).
Found at: doi:10.1371/journal.pone.0007128.s002 (2.36 MB TIF)
Figure S3 Quantitative analysis of the MBP-positive fibers
optical density in the cingulate white matter of internal controls
and sham control pups treated with either PBS or with melatonin
20 mg/kg.
Found at: doi:10.1371/journal.pone.0007128.s003 (1.99 MB TIF)
Figure S4 Quantitative analysis of Ki67+ nuclei in the cingulate
white matter according to the experimental groups at P3 and P14.
Found at: doi:10.1371/journal.pone.0007128.s004 (1.83 MB TIF)
Figure S5 Immuno-labelling of primary oligodendroglial cell
cultures using either APC or PLP at DIV6 and DIV10,
respectively with or without treatment with 1 mmol melatonin.
Found at: doi:10.1371/journal.pone.0007128.s005 (8.15 MB TIF)
Table S1 Brain weight (mean +/2 SD) from delivery to P14 of
rat pups in the experimental groups.
Found at: doi:10.1371/journal.pone.0007128.s006 (0.03 MB
DOC)
Acknowledgments
The authors wish to thank Marie Conrath, PhD and Marie-Jeanne
Brisorgeuil (UMR 7101 CNRS – Universite ´ Pierre et Marie Curie, Paris,
France) for their excellent scientific and technical electron microscopy
support.
Author Contributions
Conceived and designed the experiments: PO RHF GL CCM CV PG OB.
Performed the experiments: PO RHF GL JVS VB VM AMK JD MSA JP
OB. Analyzed the data: PO RHF GL JVS VB VM JD MSA JP PG OB.
Contributed reagents/materials/analysis tools: PO RHF VM OB. Wrote
the paper: PO AMK CCM CV PG OB.
References
1. Haynes RL, Baud O, Li J, Kinney HC, Volpe JJ, et al. (2005) Oxidative and nitrative
injury in periventricular leukomalacia: a review. Brain Pathol 15: 225–233.
2. Baud O, Greene AE, Li J, Wang H, Volpe JJ, et al. (2004) Glutathione
peroxidase-catalase cooperativity is required for resistance to hydrogen peroxide
by mature rat oligodendrocytes. J Neurosci 24: 1531–1540.
3. Fontaine RH, Olivier P, Massonneau V, Leroux P, Degos V, et al. (2008)
Vulnerability of white matter towards antenatal hypoxia is linked to a species-
dependent regulation of glutamate receptor subunits. Proc Natl Acad Sci U S A
105: 16779–16784.
4. Padilla-Gomes NF, Enrı ´quez G, Acosta-Rojas R, Perapoch J, Hernandez-
Andrade E, et al. (2007) Prevalence of neonatal ultrasound brain lesions in
premature infants with and without intrauterine growth restriction. Acta
Paediatr 96: 1582–1587.
5. Schober ME, McKnight RA, Yu X, Callaway CW, Ke X, et al. (2009)
Intrauterine growth restriction due to uteroplacental insufficiency decreased
white matter and altered NMDAR subunit composition in juvenile rat
hippocampi. Am J Physiol Regul Integr Comp Physiol 2009 296: R681–R692.
6. Jacobsson B, Ahlin K, Francis A, Hagberg G, Hagberg H, et al. (2008) Cerebral
palsy and restricted growth status at birth: population-based case-control study.
BJOG 115: 1250–1255.
7. Husson I, Mesples B, Bac P (2002) Melatoninergic neuroprotection of the
murine periventricular white matter against neonatal excitotoxic challenge. Ann
Neurol 51: 82–92.
8. Olivier P, Baud O, Evrard P, Gressens P, Verney C (2005) Prenatal ischemia
and white matter damage in rats. J Neuropathol Exp Neurol 64: 998–1006.
9. McCarthy KD, de Vellis J (1980) Preparation of separate astroglial and
oligodendroglial cell cultures from rat cerebral tissue. J Cell Biol 85: 890–
902.
10. Hetier E, Ayala J, Denefle P, Bousseau A, Rouget P, et al. (1988) Brain
macrophages synthesize interleukin-1 and interleukin-1 mRNAs in vitro.
J Neurosci Res 21: 391–397.
11. Mesples B, Fontaine RH, Lelievre V, Launay JM, Gressens P (2005) Neuronal
TGF-beta1 mediates IL-9/mast cell interaction and exacerbates excitotoxicity in
newborn mice. Neurobiol Dis 18: 193–205.
12. Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid
guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:
156–159.
13. Ishimura R, Ohsako S, Kawakami T, Sakaue M, Aoki Y, et al. (2002) Altered
protein profile and possible hypoxia in the placenta of 2,3,7,8-tetrachlorodi-
benzo-p-dioxin-exposed rats. Toxicol Appl Pharmacol 185: 197–206.
Melatonin and Myelination
PLoS ONE | www.plosone.org 12 September 2009 | Volume 4 | Issue 9 | e712814. Olivier P, Baud O, Bouslama M, Evrard P, Gressens P, et al. (2007) Moderate
growth restriction: deleterious and protective effects on white matter damage.
Neurobiol Dis 26: 253–263.
15. Nave KA (1994) Neurological mouse mutants and the genes of myelin.
J Neurosci Res 38: 607–612.
16. Riccio P, Fasano A, Borenshtein N, Bleve-Zacheo T, Kirschner DA (2000)
Multilamellar packing of myelin modeled by lipid-bound MBP. J Neurosci Res
59: 513–521.
17. Rosenbluth J (1980) Central myelin in the mouse mutant shiverer. J Comp
Neurol 194: 639–648.
18. Readhead C, Popko B, Takahashi N, Shine HD, Saavedra RA, et al. (1987)
Expression of a myelin basic protein gene in transgenic shiverer mice: correction
of the dysmyelinating phenotype. Cell 48: 703–712.
19. Sun FY, Lin X, Mao LZ, Ge WH, Zhang LM, et al. (2002) Neuroprotection by
melatonin against ischemic neuronal injury associated with modulation of DNA
damage and repair in the rat following a transient cerebral ischemia. J Pineal
Res 33: 48–56.
20. Beni SM, Kohen R, Reiter RJ, Tan DX, Shohami E (2004) Melatonin-induced
neuroprotection after closed head injury is associated with increased brain
antioxidants and attenuated late-phase activation of NF-kappaB and AP-1.
Faseb J 18: 149–151.
21. Kilic U, Kilic E, Reiter RJ (2005) Signal transduction pathways involved in
melatonin-induced neuroprotection after focal cerebral ischemia in mice. J Pineal
Res 38: 67–71.
22. Floreani M, Skaper SD, Facci L, Lipartiti M, Giusti P (1997) Melatonin
maintains glutathione homeostasis in kainic acid-exposed rat brain tissues.
Faseb J 11: 1309–1315.
23. Pei Z, Cheung RT (2003) Melatonin protects SHSY5Y neuronal cells but not
cultured astrocytes from ischemia due to oxygen and glucose deprivation.
J Pineal Res 34: 194–201.
24. Chung SY, Han SH (2003) Melatonin attenuates kainic acid-induced
hippocampal neurodegeneration and oxidative stress through microglial
inhibition. J Pineal Res 34: 95–102.
25. Welin AK, Svedin P, Lapatto R, Sultan B, Hagberg H, et al. (2007) Melatonin
reduces inflammation and cell death in white matter in the mid-gestation fetal
sheep following umbilical cord occlusion. Pediatr Res 61: 153–158.
26. Manev H, Uz T, Kharlamov A, Joo JY (1996) Increased brain damage after
stroke or excitotoxic seizures in melatonin-deficient rats. Faseb J 10: 1546–1551.
27. Tahraoui SL, Marret S, Bodenant C, Leroux P, Dommergues MA, et al. (2001)
Central role of microglia in neonatal excitotoxic lesions of the murine
periventricular white matter. Brain Pathol 11: 56–71.
28. Khwaja O, Volpe JJ (2008) Pathogenesis of cerebral white matter injury of
prematurity. Arch Dis Child Fetal Neonatal Ed 93: F153–161.
29. Lee MY, Kuan YH, Chen HY, Chen TY, Chen ST, et al. (2007) Intravenous
administration of melatonin reduces the intracerebral cellular inflammatory
response following transient focal cerebral ischemia in rats. J Pineal Res 42:
297–309.
30. Zhou J, Zhang S, Zhao X, Wei T (2008) Melatonin impairs NADPH oxidase
assembly and decreases superoxide anion production in microglia exposed to
amyloid-beta(1–42). J Pineal Res 45: 157–165.
31. Matuszak Z, Reszka K, Chignell CF (1997) Reaction of melatonin and related
indoles with hydroxyl radicals: EPR and spin trapping investigations. Free Radic
Biol Med 23: 367–372.
32. Tan DX, Manchester LC, Terron MP, Flores LJ, Reiter RJ (2007) One
molecule, many derivatives: a never-ending interaction of melatonin with
reactive oxygen and nitrogen species? J Pineal Res 42: 28–42.
33. Mohan N, Sadeghi K, Reiter RJ, Meltz ML (1995) The neurohormone
melatonin inhibits cytokine, mitogen and ionizing radiation induced NF-kappa
B. Biochem Mol Biol Int 37: 1063–1070.
34. Mayo JC, Sainz RM, Tan DX, Hardeland R, Leon J, et al. (2005) Anti-
inflammatory actions of melatonin and its metabolites, N1-acetyl-N2-formyl-5-
methoxykynuramine (AFMK) and N1-acetyl-5-methoxykynuramine (AMK), in
macrophages. J Neuroimmunol 165: 139–149.
35. Borlongan CV, Su TP, Wang Y (2000) Treatment with delta opioid peptide
enhances in vitro and in vivo survival of rat dopaminergic neurons. Neuroreport
11: 923–926.
36. Martin V, Sainz RM, Antolin I, Mayo JC, Herrera F, et al. (2002) Several
antioxidant pathways are involved in astrocyte protection by melatonin. J Pineal
Res 33: 204–212.
Melatonin and Myelination
PLoS ONE | www.plosone.org 13 September 2009 | Volume 4 | Issue 9 | e7128